5.23
전일 마감가:
$5.23
열려 있는:
$5.21
하루 거래량:
20,737
Relative Volume:
0.06
시가총액:
$322.04M
수익:
$45.15M
순이익/손실:
$-39.23M
주가수익비율:
-2.8595
EPS:
-1.829
순현금흐름:
$-18.93M
1주 성능:
-0.47%
1개월 성능:
+20.85%
6개월 성능:
-3.76%
1년 성능:
+5.75%
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
TLSI
Trisalus Life Sciences Inc
|
5.23 | 338.04M | 45.15M | -39.23M | -18.93M | -1.829 |
|
ABT
Abbott Laboratories
|
115.61 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
329.55 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
92.49 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
49.84 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
89.84 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current UpdateSegment Revenue Breakdown - Vinanet
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53AAII Bullish - Vinanet
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Raises Target Price to $14 - Moomoo
TriSalus Life Sciences (TLSI) Dips 4.3% to $5.37 as Shares Approach Key Support ZonePut Spread Alert - Vinanet
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
Securities Fraud Investigation Into TriSalus Life Sciences Inc - The National Law Review
TriSalus Life Sciences, Inc. (TLSI) stock price, news, quote and history - Yahoo Finance UK
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Q2 Earnings Call Highlights - marketbeat.com
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Warrant (TLSIW) Slumps 24% to $1.26 as Sellers Dominate the TapeIron Condor Alert - dars.gov.et
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours - Investing.com
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TLSI: Q2 revenue rose to $11.4M, with expanded OBL reimbursement and strong growth outlook - TradingView
TriSalus Q2 2026 Earnings: Gross Margin Rises as Operating Loss Widens - TradingKey
TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary - TradingView
TriSalus Life Sciences Reports Second Quarter 2026 Results - marketscreener.com
Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance - Stock Titan
TriSalus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TLSI: Q2 revenue up 1.7% to $11.4M, gross margin 88%, and 2026 guidance reaffirmed at $54–$57M - TradingView
TriSalus Life Sciences (TLSI) Gains 1.3% as Stock Holds Above Key SupportSell Signal Alerts - Vinanet
Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside - Yahoo Finance
TriSalus Life Sciences Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
TLSI Q1 2026 Earnings: Unexpected Profit of $0.03 Overwhelmingly Beats Loss EstimateOne-Time Gain Impact - Vinanet
TLSI Q1 2026 Earnings: EPS of $0.03 Beats Estimates with a 118.86% Positive SurpriseBalance Sheet Strength - Vinanet
TriSalus Life Sciences (TLSI) Stock Forum and Discussion - Moomoo
TriSalus Life Sciences Q1 2026 Earnings: EPS Surprise of 118.86% Beats Estimates Despite No Reported RevenueROA Comparison - dars.gov.et
TriSalus CEO and CFO to Join Canaccord Fireside Chat Aug. 12 - Stock Titan
TriSalus Life Sciences Inc (TLSI) Cash Flow - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Balance Sheet - TradingKey
First Light Asset Management LLC Invests $20.27 Million in TriSalus Life Sciences, Inc. $TLSI - MarketBeat
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TLSI Q1 2026 Earnings: Strong EPS Surprise as Company Focuses on PipelineLong-Term Guidance - dars.gov.et
TriSalus Life Sciences Inc (TLSI) Income Statement - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.360|Chg%:+0.040 - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.220|Chg%:-0.050 - TradingKey
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSI - TradingView
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):